Biotech & Pharma

STAT+: Pharmalittle: We're reading about biotech investors' mood, a former FDA head's confidence, and more

28 sec read0 views0 listens

Biotech investors are increasingly less concerned about political risks associated with the "Make America Healthy Again" movement, prioritizing factors like interest rates and clinical data instead. Former FDA commissioner David Kessler expresses confidence in the agency's new acting commissioner, Kyle Diamantas, viewing him as a stabilizing force despite his legal background.

This shift in investor sentiment and renewed confidence in FDA leadership could encourage more biotech innovation and investment.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

STAT+: Pharmalittle: We're reading about a Supreme Court setback for pharma, TrumpRx expands and much more

The U.S. Supreme Court declined to hear appeals from several pharmaceutical companies challenging Medicare's drug price negotiation program, a setback for brand-name drugmakers. The White House also expanded its TrumpRx platform by adding over 600 ge...

Ali Nemati

Biotech & Pharma2 days ago26 sec read

Drug Target for Fragile X Syndrome Identified Through Preclinical Study

UCLA Health researchers have identified EPAC2, a synaptic protein, as a potential therapeutic target for treating fragile X syndrome (FXS) through preclinical studies in mice. This discovery is significant because it addresses the excitation/inhibiti...

Ali Nemati

Biotech & Pharma6 days ago28 sec read

Molecular Anchors Help Tumor Therapies Stay Longer on Cancer Cells

Scientists at UCSF have created a drug carrier that physically anchors to cancer cell membranes, enhancing drug retention and effectiveness. This innovation addresses the challenge of maintaining therapeutic agents in tumor tissues long enough to be ...

Ali Nemati

Health & MedicineMay 824 sec read

Former FDA leaders, pharma speak out on mifepristone

The Supreme Court's decision on mifepristone could redefine FDA regulatory authority over abortion medications. This impacts tech professionals developing health apps and services related to reproductive health, as it may alter how digital health sol...

Ali Nemati

Biotech & PharmaMay 825 sec read

STAT+: The biotech news you need to read today

Capricor Therapeutics is suing its Japanese partner, Nippon Shinyaku and NS Pharma, for mishandling the launch preparations of their Duchenne muscular dystrophy cell therapy. This legal battle highlights risks in biotech partnerships and could affect...

Ali Nemati

STAT+: Pharmalittle: We're reading about biotech investors' mood, a former FDA head's confidence, and more

Related Articles

STAT+: Pharmalittle: We're reading about a Supreme Court setback for pharma, TrumpRx expands and much more

Drug Target for Fragile X Syndrome Identified Through Preclinical Study

Molecular Anchors Help Tumor Therapies Stay Longer on Cancer Cells

Former FDA leaders, pharma speak out on mifepristone

STAT+: The biotech news you need to read today